Atogepant for the Preventive Treatment of Migraine in Participants With Prior Treatment Failure: The ELEVATE Trial

被引：0

作者：

Pozo-Rosich, P. ^{[1
]}

Nagy, K. ^{[2
]}

Tassorelli, C. ^{[3
,4
]}

Lanteri-Minet, M. ^{[5
]}

Sacco, S. ^{[6
]}

Nezadal, T. ^{[7
]}

Finnegan, M. ^{[8
]}

Guo, H. ^{[8
]}

Gandhi, P. ^{[8
]}

Trugman, J. ^{[8
]}

机构：

[1] Vall DHebron Univ Hosp, Barcelona, Spain

[2] AbbVie, Budapest, Hungary

[3] C Mondino Fdn, Headache Sci & Neurorehabil Ctr, Pavia, Italy

[4] CHU Nice, Pain Dept, Nice, France

[5] CHU Nice, FHU InovPain, Nice, France

[6] Cote Azur Univ, Nice, France

[7] Charles Univ Prague, Mil Univ Hosp, Sch Med 1, Dept Neurol, Prague, Czech Republic

[8] AbbVie, Madison, NJ USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR-137

引用

页码：212 / 213

页数：2

共 50 条

[21] Atogepant significantly reduces mean monthly migraine days in the phase 3 trial (ADVANCE) for the preventive treatment of migraine
Ailani, J.
Lipton, R. B.
Goadsby, P. J.
Guo, H.
Miceli, R.
Severt, L.
Finnegan, M.
Trugman, J. M.
HEADACHE, 2021, 61 : 99 - 100
[22] Early Onset of Efficacy With Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
Ailani, Jessica
Reuter, Uwe
Graboski, Corrie
Klein, Brad C.
Yu, Sung Y.
Nagy, Krisztian
Guo, Hua
Trugman, Joel
CEPHALALGIA, 2022, 42 (1_SUPPL) : 32 - 33
[23] Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
Peterlin, B. Lee
Bond, Dale S.
Ailani, Jessica
Dodick, David W.
Liu, Yingyi
Ferreira, Rosa De Abreu
Smith, Jonathan H.
Dabruzzo, Brett
Goadsby, Peter J.
Trugman, Joel M.
CEPHALALGIA, 2024, 44 (12)
[24] Atogepant: an emerging treatment for migraine
Rustichelli, Cecilia
Avallone, Rossella
Ferrari, Anna
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 653 - 662
[25] Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
Koichi Hirata
Fumihiko Sakai
Takao Takeshima
Noboru Imai
Yasuhiko Matsumori
Ryuji Yoshida
Yotaro Numachi
Cheng Peng
Daniel D. Mikol
Sunfa Cheng
The Journal of Headache and Pain, 2021, 22
[26] Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial
Hirata, Koichi
Sakai, Fumihiko
Takeshima, Takao
Imai, Noboru
Matsumori, Yasuhiko
Yoshida, Ryuji
Numachi, Yotaro
Peng, Cheng
Mikol, Daniel D.
Cheng, Sunfa
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (01):
[27] Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
Ailani, Jessica
Gandhi, Pranav
Lalla, Anjana
Singh, Rashmi Halker
McAllister, Peter
Smith, Jonathan H.
Dabruzzo, Brett
Chalermpalanupap, Natty
Kelton, Kari
Nahas, Stephanie J.
HEADACHE, 2024, 64 (10): : 1253 - 1263
[28] Efficacy of Erenumab in Subjects with Episodic Migraine with Prior Preventive Treatment Failure(s)
Goadsby, Peter J.
Paemeleire, Koen
Broessner, Gregor
Brandes, Jan
Klatt, Jan
Zhang, Feng
Picard, Hernan
Mikol, Daniel
Lenz, Robert
CEPHALALGIA, 2017, 37 : 13 - 14
[29] Effect of Atogepant on Headache Impact Test-6 Among Individuals With Episodic Migraine and Preventive Treatment Failure
Tassorelli, C.
Gandhi, P.
Sacco, S.
Pozo-Rosich, P.
Lanteri-Minet, M.
Nezadal, T.
Trugman, J.
Luo, L.
Stokes, J.
Nagy, K.
EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 215 - 216
[30] Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s)
Paemeleire, Koen
Broessner, Gregor
Brandes, Jan
Klatt, Jan
Zhang, Feng
Picard, Hernan
Mikol, Daniel D.
Lenz, Robert A.
JOURNAL OF HEADACHE AND PAIN, 2017, 18

← 1 2 3 4 5 →